Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Obesity | 15 | 2023 | 654 | 3.400 |
Why?
|
Exercise | 23 | 2025 | 469 | 3.400 |
Why?
|
Diabetes Mellitus, Type 2 | 17 | 2019 | 324 | 3.030 |
Why?
|
Insulin Resistance | 19 | 2019 | 171 | 2.720 |
Why?
|
Pediatric Obesity | 6 | 2024 | 72 | 2.720 |
Why?
|
Muscle, Skeletal | 28 | 2013 | 622 | 2.610 |
Why?
|
Overweight | 6 | 2019 | 110 | 2.020 |
Why?
|
Mitochondria, Muscle | 16 | 2012 | 40 | 2.020 |
Why?
|
Blood Glucose | 20 | 2022 | 306 | 1.920 |
Why?
|
Indians, North American | 6 | 2020 | 514 | 1.880 |
Why?
|
Energy Metabolism | 10 | 2022 | 186 | 1.820 |
Why?
|
Adolescent | 29 | 2024 | 2988 | 1.820 |
Why?
|
Cardiovascular Diseases | 9 | 2017 | 353 | 1.800 |
Why?
|
Body Composition | 13 | 2019 | 262 | 1.700 |
Why?
|
Diabetes Mellitus, Type 1 | 5 | 2022 | 123 | 1.660 |
Why?
|
Muscle Proteins | 15 | 2012 | 55 | 1.640 |
Why?
|
Insulin | 21 | 2017 | 314 | 1.580 |
Why?
|
Arteries | 4 | 2014 | 65 | 1.540 |
Why?
|
Postprandial Period | 4 | 2022 | 43 | 1.490 |
Why?
|
Aging | 16 | 2012 | 952 | 1.480 |
Why?
|
Lipoproteins, LDL | 2 | 2024 | 36 | 1.430 |
Why?
|
Lipoproteins, HDL | 2 | 2024 | 41 | 1.420 |
Why?
|
Male | 62 | 2025 | 13019 | 1.390 |
Why?
|
Exercise Therapy | 4 | 2018 | 80 | 1.370 |
Why?
|
Child | 19 | 2024 | 2160 | 1.360 |
Why?
|
Mitochondrial Proteins | 12 | 2012 | 73 | 1.260 |
Why?
|
Health Promotion | 4 | 2025 | 169 | 1.180 |
Why?
|
Female | 49 | 2025 | 14633 | 1.170 |
Why?
|
Vascular Stiffness | 3 | 2024 | 41 | 1.150 |
Why?
|
Oxidative Stress | 5 | 2016 | 635 | 1.130 |
Why?
|
Humans | 70 | 2025 | 27116 | 1.130 |
Why?
|
Adenosine Triphosphate | 15 | 2012 | 116 | 1.110 |
Why?
|
Proteins | 8 | 2012 | 245 | 1.070 |
Why?
|
Amino Acids | 7 | 2019 | 81 | 1.020 |
Why?
|
Mitochondria | 11 | 2020 | 342 | 0.980 |
Why?
|
Blood Proteins | 2 | 2024 | 64 | 0.970 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2024 | 66 | 0.910 |
Why?
|
Fatty Liver | 1 | 2024 | 55 | 0.900 |
Why?
|
Heart Rate | 5 | 2022 | 375 | 0.890 |
Why?
|
Vascular Resistance | 3 | 2013 | 50 | 0.880 |
Why?
|
Nerve Growth Factors | 2 | 2014 | 24 | 0.880 |
Why?
|
Serpins | 2 | 2014 | 31 | 0.870 |
Why?
|
Biomarkers | 5 | 2024 | 738 | 0.830 |
Why?
|
Glucose Tolerance Test | 5 | 2017 | 58 | 0.780 |
Why?
|
Eye Proteins | 2 | 2014 | 197 | 0.770 |
Why?
|
Adult | 34 | 2025 | 7490 | 0.760 |
Why?
|
Oxidation-Reduction | 8 | 2022 | 355 | 0.760 |
Why?
|
Physical Fitness | 5 | 2013 | 61 | 0.740 |
Why?
|
Body Mass Index | 10 | 2017 | 389 | 0.710 |
Why?
|
Leg | 3 | 2012 | 131 | 0.680 |
Why?
|
High-Intensity Interval Training | 1 | 2020 | 9 | 0.680 |
Why?
|
Young Adult | 12 | 2024 | 2625 | 0.660 |
Why?
|
Financial Support | 1 | 2018 | 9 | 0.610 |
Why?
|
Adipose Tissue | 3 | 2019 | 180 | 0.600 |
Why?
|
Physical Endurance | 5 | 2008 | 91 | 0.600 |
Why?
|
Reward | 1 | 2018 | 45 | 0.590 |
Why?
|
DNA, Mitochondrial | 10 | 2013 | 82 | 0.580 |
Why?
|
Non-alcoholic Fatty Liver Disease | 3 | 2024 | 67 | 0.580 |
Why?
|
Peptide Hormones | 1 | 2017 | 4 | 0.570 |
Why?
|
Prednisone | 2 | 2009 | 51 | 0.570 |
Why?
|
Rest | 2 | 2015 | 94 | 0.550 |
Why?
|
Glucocorticoids | 2 | 2009 | 114 | 0.550 |
Why?
|
Risk Factors | 9 | 2019 | 2030 | 0.540 |
Why?
|
Ergometry | 1 | 2016 | 7 | 0.540 |
Why?
|
Spinal Dysraphism | 1 | 2016 | 14 | 0.530 |
Why?
|
Cerebral Palsy | 1 | 2016 | 31 | 0.520 |
Why?
|
Glycemic Index | 1 | 2016 | 5 | 0.520 |
Why?
|
Adiposity | 2 | 2016 | 88 | 0.520 |
Why?
|
Glucose | 3 | 2013 | 198 | 0.500 |
Why?
|
Amino Acids, Branched-Chain | 3 | 2019 | 8 | 0.500 |
Why?
|
Homeostasis | 2 | 2013 | 115 | 0.490 |
Why?
|
Motivation | 3 | 2025 | 210 | 0.490 |
Why?
|
Elasticity | 2 | 2013 | 49 | 0.480 |
Why?
|
Hyperemia | 2 | 2013 | 31 | 0.480 |
Why?
|
Phenylalanine | 5 | 2008 | 24 | 0.470 |
Why?
|
Blood Pressure | 3 | 2024 | 351 | 0.460 |
Why?
|
Triiodothyronine | 2 | 2006 | 20 | 0.460 |
Why?
|
Lipids | 5 | 2017 | 198 | 0.450 |
Why?
|
Trans-Activators | 2 | 2013 | 114 | 0.450 |
Why?
|
Diabetes, Gestational | 1 | 2015 | 63 | 0.450 |
Why?
|
Cross-Over Studies | 6 | 2022 | 132 | 0.440 |
Why?
|
Motor Activity | 4 | 2013 | 146 | 0.440 |
Why?
|
Muscular Atrophy | 3 | 2008 | 31 | 0.430 |
Why?
|
Diabetic Angiopathies | 3 | 2020 | 48 | 0.420 |
Why?
|
Viscera | 1 | 2012 | 18 | 0.410 |
Why?
|
Organogenesis | 1 | 2012 | 12 | 0.400 |
Why?
|
Protein Biosynthesis | 4 | 2008 | 109 | 0.400 |
Why?
|
Gene Expression Regulation | 3 | 2012 | 626 | 0.400 |
Why?
|
Meals | 2 | 2022 | 22 | 0.400 |
Why?
|
Caloric Restriction | 3 | 2012 | 73 | 0.390 |
Why?
|
Hyperlipidemias | 1 | 2012 | 36 | 0.390 |
Why?
|
Hypertension | 2 | 2012 | 305 | 0.390 |
Why?
|
Hyperglycemia | 1 | 2012 | 78 | 0.380 |
Why?
|
Liver | 6 | 2024 | 423 | 0.370 |
Why?
|
Models, Biological | 2 | 2012 | 448 | 0.370 |
Why?
|
Hyperthyroidism | 3 | 2013 | 10 | 0.350 |
Why?
|
Diet | 2 | 2009 | 225 | 0.350 |
Why?
|
Research Design | 2 | 2019 | 174 | 0.340 |
Why?
|
Insulin Antagonists | 1 | 2009 | 1 | 0.340 |
Why?
|
Oklahoma | 3 | 2019 | 978 | 0.330 |
Why?
|
RNA, Messenger | 10 | 2013 | 648 | 0.330 |
Why?
|
Video Games | 1 | 2009 | 20 | 0.320 |
Why?
|
Metabolic Syndrome | 2 | 2013 | 77 | 0.320 |
Why?
|
Hormones | 3 | 2008 | 41 | 0.320 |
Why?
|
Case-Control Studies | 2 | 2024 | 705 | 0.320 |
Why?
|
Cytoplasm | 2 | 2006 | 57 | 0.320 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2008 | 6 | 0.320 |
Why?
|
Cardiorespiratory Fitness | 2 | 2020 | 8 | 0.310 |
Why?
|
Compliance | 3 | 2014 | 21 | 0.310 |
Why?
|
Oxygen Consumption | 3 | 2001 | 179 | 0.310 |
Why?
|
Citrate (si)-Synthase | 9 | 2013 | 23 | 0.300 |
Why?
|
Human Growth Hormone | 1 | 2007 | 14 | 0.290 |
Why?
|
Myosin Heavy Chains | 2 | 2005 | 22 | 0.290 |
Why?
|
Aged | 15 | 2009 | 5221 | 0.290 |
Why?
|
Rats | 12 | 2013 | 1554 | 0.280 |
Why?
|
Membrane Transport Proteins | 3 | 2002 | 66 | 0.270 |
Why?
|
Middle Aged | 15 | 2025 | 6899 | 0.270 |
Why?
|
Diabetic Cardiomyopathies | 2 | 2017 | 6 | 0.270 |
Why?
|
Glycolysis | 1 | 2006 | 82 | 0.260 |
Why?
|
Double-Blind Method | 8 | 2015 | 405 | 0.260 |
Why?
|
Animals | 18 | 2019 | 10078 | 0.250 |
Why?
|
Dietary Fats | 2 | 2022 | 58 | 0.250 |
Why?
|
Deoxyguanosine | 1 | 2005 | 14 | 0.250 |
Why?
|
Risk | 2 | 2017 | 133 | 0.240 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2005 | 50 | 0.240 |
Why?
|
Kinetics | 7 | 2008 | 538 | 0.230 |
Why?
|
Brain Chemistry | 1 | 2004 | 22 | 0.230 |
Why?
|
Mitochondria, Liver | 1 | 2004 | 12 | 0.230 |
Why?
|
Calorimetry, Indirect | 3 | 2009 | 14 | 0.230 |
Why?
|
Feasibility Studies | 1 | 2025 | 191 | 0.230 |
Why?
|
Glucose Intolerance | 1 | 2003 | 22 | 0.220 |
Why?
|
Lipid Metabolism | 1 | 2004 | 121 | 0.220 |
Why?
|
Sequence Deletion | 1 | 2003 | 65 | 0.210 |
Why?
|
Tyrosine | 2 | 2003 | 91 | 0.210 |
Why?
|
C-Reactive Protein | 2 | 2014 | 93 | 0.210 |
Why?
|
Sex Factors | 1 | 2024 | 452 | 0.210 |
Why?
|
Leukocytes | 1 | 2003 | 68 | 0.210 |
Why?
|
Liver Cirrhosis | 1 | 2003 | 67 | 0.210 |
Why?
|
Hypoglycemic Agents | 3 | 2015 | 106 | 0.200 |
Why?
|
Peptides | 1 | 2024 | 280 | 0.200 |
Why?
|
Age Factors | 4 | 2013 | 721 | 0.190 |
Why?
|
Telemedicine | 1 | 2025 | 164 | 0.190 |
Why?
|
Rats, Sprague-Dawley | 8 | 2012 | 546 | 0.190 |
Why?
|
Reproducibility of Results | 3 | 2017 | 750 | 0.190 |
Why?
|
Aged, 80 and over | 6 | 2009 | 1940 | 0.190 |
Why?
|
Carrier Proteins | 3 | 2002 | 246 | 0.180 |
Why?
|
Biopsy | 4 | 2009 | 201 | 0.180 |
Why?
|
Exercise Test | 4 | 2013 | 248 | 0.180 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2020 | 21 | 0.180 |
Why?
|
Glucose Clamp Technique | 5 | 2015 | 12 | 0.170 |
Why?
|
Pulse Wave Analysis | 1 | 2020 | 29 | 0.170 |
Why?
|
Myocardium | 3 | 2012 | 179 | 0.170 |
Why?
|
Walking | 2 | 2013 | 130 | 0.170 |
Why?
|
Pilot Projects | 2 | 2020 | 397 | 0.170 |
Why?
|
Smoking Cessation | 1 | 2025 | 399 | 0.160 |
Why?
|
Interferon Regulatory Factors | 1 | 2019 | 57 | 0.160 |
Why?
|
Cell Adhesion Molecules | 1 | 2019 | 64 | 0.160 |
Why?
|
Muscle Fatigue | 2 | 2002 | 76 | 0.160 |
Why?
|
Weight Loss | 1 | 2019 | 72 | 0.160 |
Why?
|
Community-Based Participatory Research | 1 | 2019 | 32 | 0.160 |
Why?
|
Signal Transduction | 1 | 2005 | 1379 | 0.160 |
Why?
|
Gene Expression Profiling | 5 | 2012 | 440 | 0.160 |
Why?
|
Dietary Proteins | 2 | 2008 | 34 | 0.150 |
Why?
|
Rural Population | 1 | 2019 | 99 | 0.150 |
Why?
|
Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 3 | 0.140 |
Why?
|
Dehydroepiandrosterone | 2 | 2007 | 14 | 0.140 |
Why?
|
Dietary Carbohydrates | 1 | 1997 | 25 | 0.140 |
Why?
|
Transcription, Genetic | 3 | 2007 | 400 | 0.140 |
Why?
|
Transcription Factors | 3 | 2013 | 512 | 0.130 |
Why?
|
Prevalence | 2 | 2015 | 478 | 0.130 |
Why?
|
Eating | 2 | 2013 | 70 | 0.130 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 928 | 0.130 |
Why?
|
Child of Impaired Parents | 1 | 2015 | 6 | 0.120 |
Why?
|
Carbon Isotopes | 5 | 2012 | 43 | 0.120 |
Why?
|
Follow-Up Studies | 2 | 2011 | 988 | 0.120 |
Why?
|
Adiponectin | 1 | 2015 | 29 | 0.120 |
Why?
|
Peroxidase | 1 | 2015 | 38 | 0.120 |
Why?
|
Electric Impedance | 1 | 2015 | 30 | 0.120 |
Why?
|
Reference Values | 4 | 2006 | 199 | 0.120 |
Why?
|
Cohort Studies | 2 | 2014 | 862 | 0.120 |
Why?
|
Leptin | 1 | 2015 | 67 | 0.120 |
Why?
|
Birth Weight | 1 | 2015 | 63 | 0.120 |
Why?
|
Infant, Newborn | 2 | 2015 | 846 | 0.120 |
Why?
|
Absorptiometry, Photon | 1 | 2015 | 100 | 0.120 |
Why?
|
Glycated Hemoglobin A | 1 | 2015 | 64 | 0.120 |
Why?
|
Prospective Studies | 3 | 2015 | 1219 | 0.120 |
Why?
|
Child Development | 1 | 2015 | 72 | 0.110 |
Why?
|
RNA | 3 | 2005 | 104 | 0.110 |
Why?
|
Pregnancy | 2 | 2015 | 1149 | 0.110 |
Why?
|
Disease Progression | 2 | 2020 | 458 | 0.110 |
Why?
|
Thyroid Hormones | 1 | 2013 | 24 | 0.110 |
Why?
|
Hormone Replacement Therapy | 2 | 2006 | 8 | 0.110 |
Why?
|
Energy Intake | 4 | 2013 | 69 | 0.110 |
Why?
|
Leucine | 4 | 2012 | 20 | 0.110 |
Why?
|
Cholesterol, HDL | 1 | 2013 | 58 | 0.110 |
Why?
|
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 16 | 0.110 |
Why?
|
Mitochondrial Turnover | 1 | 2012 | 2 | 0.100 |
Why?
|
Splanchnic Circulation | 1 | 2012 | 7 | 0.100 |
Why?
|
Metabolic Diseases | 1 | 2013 | 16 | 0.100 |
Why?
|
Diazoxide | 1 | 2012 | 2 | 0.100 |
Why?
|
Sarcolemma | 1 | 2012 | 6 | 0.100 |
Why?
|
Myofibrils | 1 | 2012 | 5 | 0.100 |
Why?
|
Cardiotonic Agents | 1 | 2012 | 25 | 0.100 |
Why?
|
Blood Flow Velocity | 1 | 2012 | 63 | 0.100 |
Why?
|
Oxidative Phosphorylation | 3 | 2012 | 26 | 0.100 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 22 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2012 | 76 | 0.100 |
Why?
|
Manometry | 1 | 2011 | 36 | 0.100 |
Why?
|
Blotting, Western | 4 | 2012 | 506 | 0.100 |
Why?
|
Triglycerides | 3 | 2023 | 120 | 0.090 |
Why?
|
Rats, Inbred F344 | 3 | 2013 | 168 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2012 | 153 | 0.090 |
Why?
|
Proteomics | 3 | 2012 | 177 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 811 | 0.090 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2009 | 4 | 0.090 |
Why?
|
Hypolipidemic Agents | 1 | 2009 | 20 | 0.080 |
Why?
|
Testosterone | 2 | 2007 | 70 | 0.080 |
Why?
|
Kidney | 2 | 2008 | 276 | 0.080 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 213 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2009 | 40 | 0.080 |
Why?
|
Carotid Arteries | 1 | 2009 | 52 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2009 | 57 | 0.080 |
Why?
|
Methylprednisolone | 1 | 2009 | 15 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 325 | 0.080 |
Why?
|
Analysis of Variance | 3 | 2013 | 388 | 0.080 |
Why?
|
Physical Exertion | 1 | 2009 | 102 | 0.080 |
Why?
|
United States | 1 | 2015 | 2060 | 0.080 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2007 | 291 | 0.080 |
Why?
|
Life Style | 1 | 2008 | 83 | 0.080 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 472 | 0.080 |
Why?
|
Uncoupling Protein 3 | 3 | 2002 | 5 | 0.070 |
Why?
|
Uncoupling Protein 2 | 3 | 2002 | 5 | 0.070 |
Why?
|
Ion Channels | 3 | 2002 | 23 | 0.070 |
Why?
|
Pruritus Ani | 1 | 2007 | 1 | 0.070 |
Why?
|
Antipruritics | 1 | 2007 | 3 | 0.070 |
Why?
|
Postmenopause | 1 | 2007 | 83 | 0.070 |
Why?
|
Endothelium, Vascular | 1 | 2009 | 305 | 0.070 |
Why?
|
Electron Transport Complex IV | 3 | 2003 | 40 | 0.070 |
Why?
|
Hydrocortisone | 1 | 2007 | 88 | 0.070 |
Why?
|
Gene Expression | 3 | 2003 | 408 | 0.070 |
Why?
|
Physical Conditioning, Animal | 1 | 2006 | 38 | 0.070 |
Why?
|
Skin | 1 | 2007 | 140 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2009 | 589 | 0.060 |
Why?
|
Health | 1 | 2005 | 12 | 0.060 |
Why?
|
Risk Assessment | 2 | 2020 | 595 | 0.060 |
Why?
|
Transcriptional Activation | 1 | 2005 | 86 | 0.060 |
Why?
|
Endocrinology | 1 | 2004 | 3 | 0.060 |
Why?
|
Causality | 1 | 2004 | 13 | 0.060 |
Why?
|
Luminescent Measurements | 1 | 2004 | 30 | 0.060 |
Why?
|
Physiology | 1 | 2004 | 8 | 0.060 |
Why?
|
Administration, Oral | 1 | 2004 | 166 | 0.060 |
Why?
|
Drug Administration Schedule | 1 | 2004 | 218 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2007 | 190 | 0.060 |
Why?
|
Adaptation, Physiological | 1 | 2005 | 163 | 0.060 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2004 | 128 | 0.060 |
Why?
|
Radioactive Tracers | 1 | 2003 | 1 | 0.060 |
Why?
|
Time Factors | 3 | 2013 | 1570 | 0.060 |
Why?
|
Nuclear Respiratory Factors | 1 | 2003 | 1 | 0.060 |
Why?
|
Regional Blood Flow | 1 | 2004 | 163 | 0.060 |
Why?
|
NF-E2-Related Factor 1 | 1 | 2003 | 3 | 0.060 |
Why?
|
Nuclear Respiratory Factor 1 | 1 | 2003 | 4 | 0.050 |
Why?
|
Sample Size | 1 | 2003 | 17 | 0.050 |
Why?
|
Monosaccharide Transport Proteins | 1 | 2003 | 23 | 0.050 |
Why?
|
Fibroblast Growth Factors | 1 | 2023 | 22 | 0.050 |
Why?
|
Gene Deletion | 1 | 2003 | 116 | 0.050 |
Why?
|
Glucose Transporter Type 4 | 1 | 2003 | 62 | 0.050 |
Why?
|
Exercise Tolerance | 1 | 2003 | 82 | 0.050 |
Why?
|
Vitamin E | 1 | 2002 | 11 | 0.050 |
Why?
|
Base Sequence | 1 | 2003 | 573 | 0.050 |
Why?
|
Heart | 2 | 2001 | 221 | 0.050 |
Why?
|
Infant | 2 | 2015 | 965 | 0.050 |
Why?
|
Cell Respiration | 1 | 2001 | 9 | 0.050 |
Why?
|
Protein Isoforms | 1 | 2001 | 118 | 0.050 |
Why?
|
Mutagenesis | 1 | 2001 | 45 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2003 | 245 | 0.050 |
Why?
|
Molecular Sequence Data | 1 | 2003 | 1036 | 0.050 |
Why?
|
Oxidoreductases | 1 | 2001 | 56 | 0.050 |
Why?
|
Hyperinsulinism | 2 | 2012 | 16 | 0.040 |
Why?
|
Immune System | 1 | 2020 | 29 | 0.040 |
Why?
|
Mice | 3 | 2019 | 4472 | 0.040 |
Why?
|
Antioxidants | 1 | 2002 | 220 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2012 | 99 | 0.040 |
Why?
|
Body Weight | 3 | 2009 | 248 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 481 | 0.040 |
Why?
|
Fatty Acids, Nonesterified | 2 | 2009 | 22 | 0.040 |
Why?
|
Ventilation-Perfusion Ratio | 1 | 1997 | 12 | 0.040 |
Why?
|
Anaerobic Threshold | 1 | 1997 | 19 | 0.040 |
Why?
|
Beverages | 1 | 1997 | 24 | 0.040 |
Why?
|
MicroRNAs | 1 | 2020 | 281 | 0.030 |
Why?
|
Estradiol | 2 | 2007 | 174 | 0.030 |
Why?
|
Fetal Blood | 1 | 2015 | 38 | 0.030 |
Why?
|
Thiazolidinediones | 1 | 2015 | 10 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 1496 | 0.030 |
Why?
|
Metformin | 1 | 2015 | 34 | 0.030 |
Why?
|
Linear Models | 1 | 2015 | 201 | 0.030 |
Why?
|
Polymerase Chain Reaction | 2 | 2007 | 262 | 0.030 |
Why?
|
Hypothalamus | 1 | 2013 | 29 | 0.030 |
Why?
|
Blood Chemical Analysis | 1 | 2013 | 17 | 0.030 |
Why?
|
Body Weights and Measures | 1 | 2013 | 18 | 0.030 |
Why?
|
Electron Transport Complex II | 1 | 2012 | 5 | 0.030 |
Why?
|
Quality of Life | 2 | 2007 | 465 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2013 | 28 | 0.030 |
Why?
|
Electron Transport Complex I | 1 | 2012 | 13 | 0.030 |
Why?
|
Area Under Curve | 1 | 2013 | 94 | 0.030 |
Why?
|
Anthropometry | 1 | 2013 | 94 | 0.030 |
Why?
|
Insulin, Regular, Human | 1 | 2012 | 1 | 0.030 |
Why?
|
Microscopy, Electron | 1 | 2012 | 94 | 0.030 |
Why?
|
Self Report | 1 | 2013 | 116 | 0.020 |
Why?
|
Down-Regulation | 1 | 2012 | 198 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 101 | 0.020 |
Why?
|
Calcium | 1 | 2012 | 232 | 0.020 |
Why?
|
Adult Children | 1 | 2011 | 1 | 0.020 |
Why?
|
Transcriptome | 1 | 2012 | 205 | 0.020 |
Why?
|
Phosphorylation | 1 | 2012 | 567 | 0.020 |
Why?
|
C-Peptide | 1 | 2009 | 8 | 0.020 |
Why?
|
Glucagon | 1 | 2009 | 11 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 38 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2009 | 163 | 0.020 |
Why?
|
Sirtuins | 1 | 2008 | 17 | 0.020 |
Why?
|
Sirtuin 3 | 1 | 2008 | 18 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2008 | 48 | 0.020 |
Why?
|
Nutritional Requirements | 1 | 2008 | 9 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2008 | 19 | 0.020 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2007 | 5 | 0.020 |
Why?
|
Estrone | 1 | 2007 | 5 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2008 | 113 | 0.020 |
Why?
|
Ointments | 1 | 2007 | 6 | 0.020 |
Why?
|
Administration, Topical | 1 | 2007 | 28 | 0.020 |
Why?
|
DNA Primers | 1 | 2007 | 143 | 0.020 |
Why?
|
Treatment Failure | 1 | 2006 | 68 | 0.020 |
Why?
|
Cholesterol | 1 | 2007 | 182 | 0.020 |
Why?
|
Bone Density | 1 | 2006 | 99 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2007 | 445 | 0.020 |
Why?
|
Global Health | 1 | 2003 | 43 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2003 | 76 | 0.010 |
Why?
|
Surveys and Questionnaires | 1 | 2007 | 930 | 0.010 |
Why?
|
Substrate Specificity | 1 | 2003 | 150 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2003 | 87 | 0.010 |
Why?
|
Thermogenesis | 1 | 2003 | 12 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2003 | 135 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2002 | 46 | 0.010 |
Why?
|
Vitamin A | 1 | 2002 | 25 | 0.010 |
Why?
|
Superoxide Dismutase-1 | 1 | 2002 | 48 | 0.010 |
Why?
|
Selenium | 1 | 2002 | 17 | 0.010 |
Why?
|
Superoxide Dismutase | 1 | 2002 | 69 | 0.010 |
Why?
|
Keto Acids | 1 | 2001 | 3 | 0.010 |
Why?
|
Sarcoplasmic Reticulum | 1 | 2001 | 7 | 0.010 |
Why?
|
RNA, Transfer, Leu | 1 | 2001 | 5 | 0.010 |
Why?
|
Swine, Miniature | 1 | 2001 | 4 | 0.010 |
Why?
|
Oxygen | 1 | 2003 | 230 | 0.010 |
Why?
|
Body Fluids | 1 | 2001 | 18 | 0.010 |
Why?
|
Swine | 1 | 2001 | 220 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2007 | 2283 | 0.010 |
Why?
|